SCHEMBL2283973

SCHEMBL2283973

O=C(O)C1(O)CCc2ccccc2O1

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 2/20 0.48
SIGMAR1 Q99720 1/20 0.43
EPHX2 P34913 2/20 0.41
DRD2 P14416 1/20 0.41
HTR2A P28223 1/20 0.41
EPHX1 P07099 1/20 0.41
HCAR2 Q8TDS4 1/20 0.40
HDAC9 Q9UKV0 1/20 0.36
PPARG P37231 2/20 0.35
PPARA Q07869 2/20 0.35
SCD O00767 1/20 0.35
AKR1C1 Q04828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL2364277 0.94 TRPM8 (0.44) TRPM8SIGMAR1EPHX2DRD2HTR2A
SCHEMBL8410197 0.81 TRPM8 (0.49) TRPM8SIGMAR1EPHX2DRD2HTR2A
SCHEMBL15882569 0.79 TRPM8 (0.48) TRPM8SIGMAR1EPHX2DRD2HTR2A
SCHEMBL29455981 0.78 TRPM8 (0.47) TRPM8SIGMAR1PPARGPPARA
SCHEMBL3519974 0.78 TRPM8 (0.47) TRPM8SIGMAR1PPARGPPARA
SCHEMBL4551228 0.77 TRPM8 (0.46) TRPM8SIGMAR1EPHX2DRD2HTR2A
SCHEMBL462820 0.76 SIGMAR1 (0.45) TRPM8SIGMAR1EPHX2DRD2HTR2A
SCHEMBL6467973 0.76 SIGMAR1 (0.45) TRPM8SIGMAR1EPHX2DRD2HTR2A
SCHEMBL30613915 0.74 PPARG (0.59) TRPM8SIGMAR1PPARGPPARA
SCHEMBL16635226 0.74 PPARG (0.59) TRPM8SIGMAR1PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-57145871-A None JP disclosed
WO-2024010441-A1 A SELF-EMULSIFYING DRUG DELIVERY FORMULATION WITH IMPROVED ORAL BIOAVAILABILITY OF LIPOPHILIC COMPOUND AVANTSAR SDN BHD (MY) 2024-01-11 WO disclosed
US-20220160759-A1 NOVEL COMPOSITIONS FOR TREATING COLITIS AND/OR PREVENTING COLON CANCER PURDUE RESEARCH FOUNDATION (US) 2022-05-26 US disclosed
CN-108349929-B Tocotrienol derivatives, pharmaceutical compositions and methods of use in 5-lipoxygenase related disorders 昂热大学 2022-01-11 CN disclosed
US-20190144413-A1 TOCOTRIENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN 5-LIPOXYGENASE RELATED DISEASES FRIEDRICH-SCHILLER-UNIVERSITÄT JENA (DE) 2019-05-16 US disclosed
EP-3341366-A1 TOCOTRIENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN 5-LIPOXYGENASE RELATED DISEASES Université d'Angers (FR) 2018-07-04 EP disclosed
US-20170296505-A1 LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS PURDUE RESEARCH FOUNDATION (US) 2017-10-19 US disclosed
US-20170296505-A1 LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS PURDUE RESEARCH FOUNDATION (US) 2017-10-19 US disclosed
US-9676744-B2 Long-chain carboxychromanols and analogs for use as anti-inflammatory agents PURDUE RESEARCH FOUNDATION (US) 2017-06-13 US disclosed
US-9676744-B2 Long-chain carboxychromanols and analogs for use as anti-inflammatory agents PURDUE RESEARCH FOUNDATION (US) 2017-06-13 US disclosed
US-8822529-B2 Long-chain carboxychromanols and analogs for use as anti-inflammatory agents PURDUE RESEARCH FOUNDATION (US) 2014-09-02 US disclosed
US-8822529-B2 Long-chain carboxychromanols and analogs for use as anti-inflammatory agents PURDUE RESEARCH FOUNDATION (US) 2014-09-02 US disclosed
US-20110207808-A1 LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS PURDUE RESEARCH FOUNDATION (US) 2011-08-25 US disclosed
US-20110207808-A1 LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS PURDUE RESEARCH FOUNDATION (US) 2011-08-25 US disclosed
WO-2010033687-A1 LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS PURDUE RESEARCH FOUNDATION (US) 2010-03-25 WO disclosed
WO-2010033687-A1 LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS PURDUE RESEARCH FOUNDATION (US) 2010-03-25 WO disclosed
EP-1178994-B1 IMPROVED PROCESS FOR PHOSPHORYLATION VITAL HEALTH SCIENCES PTY LTD (AU) 2007-10-31 EP disclosed
US-5348973-A Resolution of hydroxychroman-2-carboxylic acid esters by enantiomeric hydrolysis RHONE-POULENC CHIMIE (FR) 1994-09-20 US disclosed
EP-0183869-B1 CHROMAN COMPOUNDS AND THEIR USE KURARAY CO., LTD. (JP) 1991-04-17 EP disclosed
JP-S57145871-A CHROMANOLCARBOXYLIC DERIVATIVE EISAI CO LTD 1982-09-09 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144413-A1 TOCOTRIENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN 5-LIPOXYGENASE RELATED DISEASES ALOX5, ALOX15B, ALOX15 TRPM8 1719/4885SIGMAR1 3053/4885EPHX2 122/4885
US-20110207808-A1 LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS ALOX12, ALOX5, ALOX15 TRPM8 3243/4885SIGMAR1 1228/4885EPHX2 50/4885
US-20170296505-A1 LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS ALOX12, ALOX5, PTGS1 TRPM8 3141/4885SIGMAR1 1154/4885EPHX2 55/4885
US-20220160759-A1 NOVEL COMPOSITIONS FOR TREATING COLITIS AND/OR PREVENTING COLON CANCER LBR, LTA, IL23R TRPM8 4110/4885SIGMAR1 1665/4885EPHX2 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.